DelveInsight’s ‘Type 1 Diabetes Pipeline Insight 2023‘ report provides comprehensive global coverage of pipeline Type 1 Diabetes therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Type 1 Diabetes pipeline domain.
For Type 1 Diabetes emerging drugs, the Type 1 Diabetes pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Type 1 Diabetes Pipeline Report
- DelveInsight’s Type 1 Diabetes Pipeline analysis depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Type 1 Diabetes treatment.
- The leading Type 1 Diabetes companies include Landos Biopharma, Zealand Pharma, Prevention Bio, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Novartis, ImCyse, , Tolerion, Avotres, REMD Biotherapeutics, Novo Nordisk, Eledon Pharmaceuticals, Avotres, Eli Lilly and Company, GEROPHARM, Regeneron Pharmaceuticals, Diamyd Medical, NextCell Pharma, Novartis, ViaCyte, Op-T LLC, Dompe Farmaceutici, ILTOO Pharma, Throne Biotechnologies, Oramed, Adocia, Imcyse, Janssen Biotech, Xeris Pharmaceuticals, Zealand Pharma, Jaguar Gene Therapy, SQZ Biotech, Enthera, and others are evaluating their lead assets to improve the Type 1 Diabetes treatment landscape.
- Key Type 1 Diabetes pipeline therapies in various stages of development include LABP 111, TTP 399, Teplizumab, Emricasan, VX 880, Encapsulated islet cell program, Eflornithine oral, Iscalimab, IMCY 0098, AT-1501, TOL 3021, AVT001, Volagidemab, NNC0363 0845, NNC0268-0965, LY 3209590, GP40071, Autoimmune diabetes vaccine, ProTrans, MHS 552, VC-02, OPT101, VC-01, Ladarixin, Aldesleukin, Stem Cell Educator therapy, ORMD-0801, ADO09, IMCY-0098, Glucagon intranasal, Golimumab, LY 900027, PRAM9JAG301, Dasiglucagon, SQZ TAC research program, Ent001, and others.
- In July 2023, the FDA approved CellTrans’s Lantidra allogeneic pancreatic islet cellular therapy for the treatment of type 1 diabetes.
- In July 2022, Vertex Pharmaceuticals announced that the company has entered into a definitive agreement under which Vertex will acquire ViaCyte, a privately held biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D), for $320 million in cash.
- In June 2022, Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) lifted the clinical hold placed on the Phase I/II clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D) with impaired hypoglycemia awareness and severe hypoglycemia.
Request a sample and discover the recent breakthroughs happening in the Type 1 Diabetes pipeline landscape @ Type 1 Diabetes Pipeline Outlook
Type 1 Diabetes Overview
Type 1 diabetes mellitus (T1DM) is an autoimmune disease that involves the loss of insulin-producing pancreatic beta cells. Insulin is a required anabolic hormone that regulates glucose, lipid, protein, and mineral metabolism, as well as growth. The specific causes of type 1 diabetes remain uncertain. T1DM develops in three stages. Stage 1 is asymptomatic and is characterized by normal fasting glucose, normal glucose tolerance, and the presence of more than or equal to two pancreatic autoantibodies. More than two pancreatic autoantibodies and dysglycemia: impaired fasting glucose (glucose of 100 to 125 mg/dL) or impaired glucose tolerance (2-hour PG of 140 to 199 mg/dL) or a hemoglobin A1c of 5.7% to 6.4% are stage 2 diagnostic criteria. Individuals remain asymptomatic. Diabetes or hyperglycemia with clinical symptoms and two or more pancreatic autoantibodies characterize stage 3. Type 1 diabetes symptoms include frequent urination, weight loss, impaired eyesight, weariness, weakness, and others. The blood test is the most prevalent approach for diagnosing type 1 diabetes.
Find out more about Type 1 Diabetes medication @ New Drug for Type 1 Diabetes
Type 1 Diabetes Treatment Analysis: Drug Profile
Emricasan: Histogen
Emricasan is an orally active, first-in-class pan-caspase inhibitor with the potential to lower the activity of enzymes that promote inflammation and apoptosis. As part of its 2020 merger with Conatus Pharmaceuticals Inc., Histogen obtained certain rights to emricasan and other caspase inhibitor medicines.
VX-880: Vertex Pharmaceuticals
VX-880 is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell treatment produced utilizing proprietary technology. VX-880 is being tested in patients with T1D who have impaired hypoglycemic awareness and severe hypoglycemia. VX-880 has the potential to restore the body’s ability to manage glucose levels by restoring pancreatic islet cell activity, including glucose-responsive insulin production. VX-880 is infused into the hepatic portal vein and requires ongoing immunosuppressive medication to protect the islet cells from immunological rejection.
Key Type 1 Diabetes Therapies and Companies
- Teplizumab: Prevention Bio
- Dasiglucagon: Zealand Pharma
- AT-1501: Eledon Pharmaceuticals
- AVT001: Avotres
- IMCY-0098: ImCyse
- Iscalimab: Novartis
- Emricasan: Histogen
- VX-880: Vertex Pharmaceuticals
- NNC0363 0845: Novo Nordisk
- Eflornithine: Panbela Therapeutics
- LABP 111: Landos Biopharma
Learn more about the novel and emerging Type 1 Diabetes pipeline therapies @ Type 1 Diabetes Clinical Trials
Type 1 Diabetes Therapeutics Assessment
- By Product Type
- Monotherapy
- Combination Therapy
- By Stage
- Discovery
- Pre-Clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
- By Route of Administration
-
- Intravenous
- Oral
- Subcutaneous
- By Molecule Type
- Cell therapy
- Peptide
- Small molecule
- Polymer
- Gene therapy
Scope of the Type 1 Diabetes Pipeline Report
- Coverage: Global
- Key Type 1 Diabetes Companies: Landos Biopharma, Zealand Pharma, Prevention Bio, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Novartis, ImCyse, , Tolerion, Avotres, REMD Biotherapeutics, Novo Nordisk, Eledon Pharmaceuticals, Avotres, Eli Lilly and Company, GEROPHARM, Regeneron Pharmaceuticals, Diamyd Medical, NextCell Pharma, Novartis, ViaCyte, Op-T LLC, Dompe Farmaceutici, ILTOO Pharma, Throne Biotechnologies, Oramed, Adocia, Imcyse, Janssen Biotech, Xeris Pharmaceuticals, Zealand Pharma, Jaguar Gene Therapy, SQZ Biotech, Enthera, and others.
- Key Type 1 Diabetes Pipeline Therapies: LABP 111, TTP 399, Teplizumab, Emricasan, VX 880, Encapsulated islet cell program, Eflornithine oral, Iscalimab, IMCY 0098, AT-1501, TOL 3021, AVT001, Volagidemab, NNC0363 0845, NNC0268-0965, LY 3209590, GP40071, Autoimmune diabetes vaccine, ProTrans, MHS 552, VC-02, OPT101, VC-01, Ladarixin, Aldesleukin, Stem Cell Educator therapy, ORMD-0801, ADO09, IMCY-0098, Glucagon intranasal, Golimumab, LY 900027, PRAM9JAG301, Dasiglucagon, SQZ TAC research program, Ent001, and others.
Dive deep into rich insights for drugs used for Type 1 Diabetes treatment; visit @ Type 1 Diabetes Drugs
Table of Contents
| 1. | Introduction |
| 2. | Executive Summary |
| 3. | Type 1 Diabetes Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Type 1 Diabetes Pipeline Therapeutics |
| 6. | Type 1 Diabetes Pipeline: Late Stage Products (Phase III) |
| 7. | Type 1 Diabetes Pipeline: Late Stage Products (Phase III) |
| 8. | Type 1 Diabetes Pipeline: Mid-Stage Products (Phase II) |
| 9. | Type 1 Diabetes Pipeline: Early Stage Products (Phase I) |
| 10. | Therapeutic Assessment |
| 11. | Inactive Products |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the Type 1 Diabetes therapy in the pipeline, reach out @ Type 1 Diabetes Medication
Related Reports
Type 1 Diabetes Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 1 diabetes companies including Histogen, Novo Nordisk, Prevention Bio, among others.
Type 1 Diabetes Epidemiology Forecast
Type 1 Diabetes Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical and forecasted type 1 diabetes epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Diabetes Pipeline Insights, 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diabetes companies, including Prevention Bio, Zealand Pharma, Novo Nordisk, among others.
Diabetes Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetes companies, including TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk, among others.
Type 2 Diabetes Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 2 diabetes companies, including Sanofi, Eli Lilly and Company, AstraZeneca, Novartis, among others.
Type 2 Diabetes Pipeline Insight, 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key type 2 diabetes companies, including Sanofi, Eli Lilly and Company, Novartis, among others.
Other Trending Reports
3d Cardiac Mapping System Market | Acute Pulmonary Embolism Market | Aortic Stenosis Market | Bile Duct Neoplasm Market | Carcinoid Tumor Market | Cluster Headache Market | Condyloma Market | Familial Primary Pulmonary Hypertension Market | Fibrocystic Breast Condition Market | Meningioma Market | Progressive Multifocal Leukoencephalopathy Market | Rhino Conjunctivitis Market | Ventilator Market |Intracranial Pressure Monitoring Devices Market | Hemodynamic Monitoring Systems Market | Automated External Defibrillators Market | Neurostimulation Devices Market | Neuroprosthetics Market | Eczema Market | Foot And Ankle Devices Market | Neuroblastoma Market | Pharmaceutical Consulting Companies | Allergic Conjunctivitis Market | Biotech Consulting | Cervical Intraepithelial Neoplasia Market | Osteoarthritis Market | Pruritus Market | Capnography Device Market | Image Guided Surgery Devices Market | Opioid Induced Constipation Market | Alzheimer Disease Market | Angioedema Market | Neurovascular Devices Market | Actinic Keratosis Market | Acute Coronary Syndrome Market | Blood Gas And Electrolyte Analyzers Market
Related Healthcare Services
- Healthcare Consulting
- Healthcare Competitive Intelligence Services
- Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect With Us at LinkedIn | Facebook | Twitter
Contact Us
Sandeep Joshi
info@delveinsight.com
+1(919)321-6187